• In recent days, Tata Consultancy Services announced a collaboration with Advanced Micro Devices to co-develop industry-specific AI and generative AI solutions that help enterprises move projects from pilots to full production using AMD’s high-performance computing portfolio across cloud and edge environments.
• A distinctive aspect of this collaboration is TCS’s plan to rapidly upskill thousands of engineers on AMD CPUs, GPUs, NPUs and embedded platforms, potentially deepening AMD’s reach into sectors such as life sciences, manufacturing, and financial services through ready-made AI frameworks.
• We’ll now examine how TCS’s plan to industrialize AMD-powered AI solutions at scale could influence the company’s existing investment narrative.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 38 companies in the world exploring or producing it. Find the list for free.

Advanced Micro Devices Investment Narrative Recap

To own AMD today, you generally have to believe its data center and AI franchises can scale into a much larger, higher margin business, while the stock’s premium valuation is eventually supported by strong earnings growth. The TCS collaboration reinforces that narrative by pushing AMD hardware deeper into real enterprise AI deployments, though the near term share price still looks most sensitive to upcoming Q4 results and any signs that hyperscaler demand or AI accelerator ramps might slow.

Among recent announcements, the TCS partnership stands out as most relevant here because it explicitly aims to “industrialize” AMD powered AI across cloud and edge, using EPYC CPUs, Instinct GPUs and embedded SoCs. If TCS successfully standardizes on AMD platforms in areas like life sciences and financial services, that could incrementally support the consensus catalyst of accelerating data center and AI revenue, while leaving competitive, regulatory and supply chain risks firmly in focus.

Yet even with these AI wins, investors should be aware that rising export controls and tariffs on select AMD AI chips could still materially affect...

Advanced Micro Devices' narrative projects $46.2 billion revenue and $9.0 billion earnings by 2028. This requires 18.5% yearly revenue growth and a roughly $6.8 billion earnings increase from $2.2 billion today.

Uncover how Advanced Micro Devices' forecasts yield a $283.57 fair value, a 27% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already factoring in just 14.8% annual revenue growth to about US$44.8 billion by 2028, and in light of export control and tariff headlines, their more cautious view on AMD’s long term AI opportunity shows how far expectations can differ and why it is worth comparing more than one narrative before you decide what you believe.

Explore 92 other fair value estimates on Advanced Micro Devices - why the stock might be worth as much as 62% more than the current price!

Build Your Own Advanced Micro Devices Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Advanced Micro Devices research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Advanced Micro Devices research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Advanced Micro Devices' overall financial health at a glance.

Curious About Other Options?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.